Search results
Search for "manufacture" in Full Text gives 56 result(s) in Beilstein Journal of Organic Chemistry.
Synthesis of compounds related to the anti-migraine drug eletriptan hydrobromide
- Suri Babu Madasu,
- Nagaji Ambabhai Vekariya,
- M. N. V. D. Hari Kiran,
- Badarinadh Gupta,
- Aminul Islam,
- Paul S. Douglas and
- Korupolu Raghu Babu
Beilstein J. Org. Chem. 2012, 8, 1400–1405, doi:10.3762/bjoc.8.162
- Chemistry Department, AU College of Engineering, Andhra University, Visakhapatnam-530003, Andhra Pradesh, India 10.3762/bjoc.8.162 Abstract Eletriptan hydrobromide (1) is a selective serotonin (5-HT1) agonist, used for the acute treatment of the headache phase of migraine attacks. During the manufacture of
- of eletriptan hydrobromide is 97 mg per day, which is equivalent to 80 mg of eletriptan base [10]. During the manufacture of eletriptan hydrobromide (1), many process-related impurities have been identified. As per ICH guide lines the acceptable level for known and unknown related impurities in the
Graphical Abstract
Figure 1: Related compounds of eletriptan hydrobromide.
Scheme 1: Synthetic route of eletriptan hydrobromide. Reagents and conditions: (i) Acetic anhydride, TEA, DMF...
Scheme 2: Dimerization of 13. Reagents and conditions: (i) NaH, THF, 30–35 °C, 2 h; 11.6% yield after column ...
Scheme 3: Formation of the isomers 3 and 4. Reagents and conditions: (i) Aqueous hydrogen peroxide, methanol,...
Scheme 4: Synthesis of impurity 5. Reagents and conditions: (i) Acetic anhydride, TEA, DMF, 90–100 °C; (ii) p...
Scheme 5: Debromination of 9 to 6. Reagents and conditions: Palladium on carbon, ethanol, ca. 7 bar, 25–30 °C...
Scheme 6: Formation of 7. Reagents, conditions: (i) (a) K2CO3, methanol, reflux, 2 days; 40% yield after colu...
Scheme 7: Synthesis of the tetracyclic compound 7. Reagents and conditions: (i) aqueous hydrogen peroxide, wa...
Chimeric self-sufficient P450cam-RhFRed biocatalysts with broad substrate scope
- Aélig Robin,
- Valentin Köhler,
- Alison Jones,
- Afruja Ali,
- Paul P. Kelly,
- Elaine O'Reilly,
- Nicholas J. Turner and
- Sabine L. Flitsch
Beilstein J. Org. Chem. 2011, 7, 1494–1498, doi:10.3762/bjoc.7.173
- Manufacture (CoEBio3) and the Royal Society (Wolfson Merit Award to SLF) for financial support.
Graphical Abstract
Figure 1: Oxidation reactions with P450cam-RhFRed mutants.
Scheme 1: Whole cell biotransformation of diphenylmethane to 4-hydroxydiphenylmethane with P450cam(Y96A)-RhFR...
Efficient and selective chemical transformations under flow conditions: The combination of supported catalysts and supercritical fluids
- M. Isabel Burguete,
- Eduardo García-Verdugo and
- Santiago V. Luis
Beilstein J. Org. Chem. 2011, 7, 1347–1359, doi:10.3762/bjoc.7.159
- ][84]. As a result, the chemical industry is currently exploring the great potential of biocatalysis to manufacture both bulk and fine chemicals [85][86]. Although many of the reported examples involve the use of batch conditions, different examples of continuous biocatalytic processes have been
Graphical Abstract
Scheme 1: Hydrogenation of ethyl pyruvate.
Scheme 2: Hydrogenation of dimethyl itaconate.
Scheme 3: a) Enantioselective hydrogenation of N-(1-phenylethylidene)aniline in IL–CO2; b) Enantioselective h...
Scheme 4: Selective hydroformylation with a silica supported Rh catalyst.
Scheme 5: Enantioselective hydroformylation of styrene.
Scheme 6: Enantioselective hydrovinylation of styrene.
Scheme 7: Enantioselective cyclopropanation of styrene catalyzed by supported Cu–BOX, Cu–PyOX and Rh–PyBOX ca...
Scheme 8: Continuous hydrogenation of acetophenone coupled with the kinetic resolution of the product.
Scheme 9: Kinetic resolution of phenylethanol using CALB immobilized in ILs and supported ILs.
An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals
- Marcus Baumann,
- Ian R. Baxendale,
- Steven V. Ley and
- Nikzad Nikbin
Beilstein J. Org. Chem. 2011, 7, 442–495, doi:10.3762/bjoc.7.57
- reaction conditions and gave rise to numerous by-products. An improved route was developed for the compounds large scale manufacture. The refined process route (Scheme 56) starts with a sequential bis-acylation of hydrazine with ethyl trifluoroacetate and chloroacetyl chloride [85]. The resulting hydrazide
Graphical Abstract
Figure 1: Structures of atorvastatin and other commercial statins.
Figure 2: Structure of compactin.
Scheme 1: Synthesis of pentasubstituted pyrroles.
Scheme 2: [3 + 2] Cycloaddition to prepare 5-isopropylpyrroles.
Scheme 3: Regiospecific [3 + 2] cycloaddition to prepare the pyrrole scaffold.
Scheme 4: Formation of the pyrrole core of atorvastatin via [3 + 2] cycloaddition.
Scheme 5: Formation of pyrrole 33 via the Paal–Knorr reaction.
Scheme 6: Convergent synthesis towards atorvastatin.
Figure 3: Binding pocket of sunitinib in the TRK KIT.
Scheme 7: Synthesis of sunitinib.
Scheme 8: Alternative synthesis of sunitinib.
Scheme 9: Key steps in the syntheses of sumatriptan and zolmitriptan.
Scheme 10: Introduction of the N,N-dimethylaminoethyl side chain.
Scheme 11: Japp–Klingemann reaction in the synthesis of sumatriptan.
Scheme 12: Synthesis of the intermediate sulfonyl chlorides 62 and 63.
Scheme 13: Alternative introduction of the sulfonamide.
Scheme 14: Negishi-type coupling to benzylic sulfonamides.
Scheme 15: Heck reaction used to introduce the sulfonamide side chain of naratriptan.
Scheme 16: Synthesis of the oxazolinone appendage of zolmitriptan.
Scheme 17: Grandberg indole synthesis used in the preparation of rizatriptan.
Scheme 18: Improved synthesis of rizatriptan.
Scheme 19: Larock-type synthesis of rizatriptan.
Scheme 20: Synthesis of eletriptan.
Scheme 21: Heck coupling for the indole system in eletriptan.
Scheme 22: Attempted Fischer indole synthesis of elatriptan.
Scheme 23: Successful Fischer indole synthesis for eletriptan.
Scheme 24: Mechanistic rationale for the Bischler–Möhlau reaction.
Scheme 25: Bischler-type indole synthesis used in the fluvastatin sodium synthesis.
Scheme 26: Palladium-mediated synthesis of ondansetron.
Scheme 27: Fischer indole synthesis of ondansetron.
Scheme 28: Optimised Pictet–Spengler reaction towards tadalafil.
Figure 4: Structures of carvedilol 136 and propranolol 137.
Scheme 29: Synthesis of the carbazole core of carvedilol.
Scheme 30: Alternative syntheses of 4-hydroxy-9H-carbazole.
Scheme 31: Convergent synthesis of etodolac.
Scheme 32: Alternative synthesis of etodolac.
Figure 5: Structures of imidazole-containing drugs.
Scheme 33: Synthesis of functionalised imidazoles towards losartan.
Scheme 34: Direct synthesis of the chlorinated imidazole in losartan.
Scheme 35: Synthesis of trisubstituted imidazoles.
Scheme 36: Preparation of the imidazole ring in olmesartan.
Scheme 37: Synthesis of ondansetron.
Scheme 38: Alternative route to ondansetron and its analogues.
Scheme 39: Proton pump inhibitors and synthesis of esomeprazole.
Scheme 40: Synthesis of benzimidazole core pantoprazole.
Figure 6: Structure of rabeprazole 194.
Scheme 41: Synthesis of candesartan.
Scheme 42: Alternative access to the candesartan key intermediate 216.
Scheme 43: .Medicinal chemistry route to telmisartan.
Scheme 44: Improved synthesis of telmisartan.
Scheme 45: Synthesis of zolpidem.
Scheme 46: Copper-catalysed 3-component coupling towards zolpidem.
Figure 7: Structure of celecoxib.
Scheme 47: Preparation of celecoxib.
Scheme 48: Alternative synthesis of celecoxib.
Scheme 49: Regioselective access to celecoxib.
Scheme 50: Synthesis of pazopanib.
Scheme 51: Syntheses of anastrozole, rizatriptan and letrozole.
Scheme 52: Regioselective synthesis of anastrozole.
Scheme 53: Triazine-mediated triazole formation towards anastrozole.
Scheme 54: Alternative routes to 1,2,4-triazoles.
Scheme 55: Initial synthetic route to sitagliptin.
Figure 8: Binding of sitagliptin within DPP-IV.
Scheme 56: The process route to sitagliptin key intermediate 280.
Scheme 57: Synthesis of maraviroc.
Scheme 58: Synthesis of alprazolam.
Scheme 59: The use of N-nitrosoamidine derivatives in the preparation of fused benzodiazepines.
Figure 9: Structures of itraconazole, ravuconazole and voriconazole.
Scheme 60: Synthesis of itraconazole.
Scheme 61: Synthesis of rufinamide.
Scheme 62: Representative tetrazole formation in valsartan.
Figure 10: Structure of tetrazole containing olmesartan, candesartan and irbesartan.
Scheme 63: Early stage introduction of the tetrazole in losartan.
Scheme 64: Synthesis of cilostazol.
Figure 11: Structure of cefdinir.
Scheme 65: Semi-synthesis of cefdinir.
Scheme 66: Thiazole syntheses towards ritonavir.
Scheme 67: Synthesis towards pramipexole.
Scheme 68: Alternative route to pramipexole.
Scheme 69: Synthesis of famotidine.
Scheme 70: Efficient synthesis of the hyperuricemic febuxostat.
Scheme 71: Synthesis of ziprasidone.
Figure 12: Structure of mometasone.
Scheme 72: Industrial access to 2-furoic acid present in mometasone.
Scheme 73: Synthesis of ranitidine from furfuryl alcohol.
Scheme 74: Synthesis of nitrofurantoin.
Scheme 75: Synthesis of benzofuran.
Scheme 76: Synthesis of amiodarone.
Scheme 77: Synthesis of raloxifene.
Scheme 78: Alternative access to the benzo[b]thiophene core of raloxifene.
Scheme 79: Gewald reaction in the synthesis of olanzapine.
Scheme 80: Alternative synthesis of olanzapine.
Figure 13: Access to simple thiophene-containing drugs.
Scheme 81: Synthesis of clopidogrel.
Scheme 82: Pictet–Spengler reaction in the preparation of tetrahydrothieno[3,2-c]pyridine (422).
Scheme 83: Alternative synthesis of key intermediate 422.
Figure 14: Co-crystal structures of timolol (left) and carazolol (right) in the β-adrenergic receptor.
Scheme 84: Synthesis of timolol.
Scheme 85: Synthesis of tizanidine 440.
Scheme 86: Synthesis of leflunomide.
Scheme 87: Synthesis of sulfamethoxazole.
Scheme 88: Synthesis of risperidone.
Figure 15: Relative abundance of selected transformations.
Figure 16: The abundance of heterocycles within top 200 drugs (5-membered rings).
Aromatic and heterocyclic perfluoroalkyl sulfides. Methods of preparation
- Vladimir N. Boiko
Beilstein J. Org. Chem. 2010, 6, 880–921, doi:10.3762/bjoc.6.88
Graphical Abstract
Figure 1: Examples of industrial fluorine-containing bio-active molecules.
Figure 2: CF3(S)- and CF3(O)-containing pharmacologically active compounds.
Figure 3: Hypotensive candidates with SRF and SO2RF groups – analogues of Losartan and Nifedipin.
Figure 4: The variety of the pharmacological activity of RFS-substituted compounds.
Figure 5: Recent examples of compounds containing RFS(O)n-groups [12-18].
Scheme 1: Fluorination of ArSCCl3 to corresponding ArSCF3 derivatives. For references see: a[38-43]; b[41,42]; c[43]; d[44]; e[38-43,45-47]; f[38-43,48,49]; g...
Scheme 2: Preparation of aryl pentafluoroethyl sulfides.
Scheme 3: Mild fluorination of the aryl SCF2Br derivatives.
Scheme 4: HF fluorinations of aryl α,α,β-trichloroisobutyl sulfide at various conditions.
Scheme 5: Monofluorination of α,α-dichloromethylene group.
Scheme 6: Electrophilic substitution of phenols with CF3SCl [69].
Scheme 7: Introduction of SCF3 groups into activated phenols [71-74].
Scheme 8: Preparation of tetrakis(SCF3)-4-methoxyphenol [72].
Scheme 9: The interactions of resorcinol and phloroglucinol derivatives with RFSCl.
Scheme 10: Reactions of anilines with CF3SCl.
Scheme 11: Trifluoromethylsulfanylation of anilines with electron-donating groups in the meta position [74].
Scheme 12: Reaction of benzene with CF3SCl/CF3SO3H [77].
Scheme 13: Reactions of trifluoromethyl sulfenyl chloride with aryl magnesium and -mercury substrates.
Scheme 14: Reactions of pyrroles with CF3SCl.
Scheme 15: Trifluoromethylsulfanylation of indole and indolizines.
Scheme 16: Reactions of N-methylpyrrole with CF3SCl [80,82].
Scheme 17: Reactions of furan, thiophene and selenophene with CF3SCl.
Scheme 18: Trifluoromethylsulfanylation of imidazole and thiazole derivatives [83].
Scheme 19: Trifluoromethylsulfanylation of pyridine requires initial hydride reduction.
Scheme 20: Introduction of additional RFS-groups into heterocyclic compounds in the presence of CF3SO3H.
Scheme 21: Introduction of additional RFS-groups into pyrroles [82,87].
Scheme 22: By-products in reactions of pyrroles with CF3SCl [82].
Scheme 23: Reaction of aromatic iodides with CuSCF3 [93,95].
Scheme 24: Reaction of aromatic iodides with RFZCu (Z = S, Se), RF = CF3, C6F5 [93,95,96].
Scheme 25: Side reactions during trifluoromethylsulfanylation of aromatic iodides with CF3SCu [98].
Scheme 26: Reactions with in situ generated CuSCF3.
Scheme 27: Perfluoroalkylthiolation of aryl iodides with bulky RFSCu [105].
Scheme 28: In situ formation and reaction of RFZCu with aryl iodides.
Figure 6: Examples of compounds obtained using in situ generated RFZCu methodology [94].
Scheme 29: Introduction of SCF3 group into aromatics via difluorocarbene.
Scheme 30: Tetrakis(dimethylamino)ethylene dication trifluoromethyl thiolate as a stable reagent for substitut...
Scheme 31: The use of CF2=S/CsF or (CF3S)2C=S/CsF for the introduction of CF3S groups into fluorinated heteroc...
Scheme 32: One-pot synthesis of ArSCF3 from ArX, CCl2=S and KF.
Scheme 33: Reaction of aromatics with CF3S− Kat+ [115].
Scheme 34: Reactions of activated aromatic chlorides with AgSCF3/KI.
Scheme 35: Comparative CuSCF3/KI and Hg(SCF3)2/KI reactions.
Scheme 36: Me3SnTeCF3 – a reagent for the introduction of the TeCF3 group.
Scheme 37: Sandmeyer reactions with CuSCF3.
Scheme 38: Reactions of perfluoroalkyl iodides with alkali and organolithium reagents.
Scheme 39: Perfluoroalkylation with preliminary breaking of the disulfide bond.
Scheme 40: Preparation of RFS-substituted anilines from dinitrodiphenyl disulfides.
Scheme 41: Photochemical trifluoromethylation of 2,4,6-trimercaptochlorobenzene [163].
Scheme 42: Putative process for the formation of B, C and D.
Scheme 43: Trifluoromethylation of 2-mercapto-4-hydroxy-6-trifluoromethylyrimidine [145].
Scheme 44: Deactivation of 2-mercapto-4-hydroxypyrimidines S-centered radicals.
Scheme 45: Perfluoroalkylation of thiolates with CF3Br under UV irradiation.
Scheme 46: Catalytic effect of methylviologen for RF• generation.
Scheme 47: SO2−• catalyzed trifluoromethylation.
Scheme 48: Electrochemical reduction of CF3Br in the presence of SO2 [199,200].
Scheme 49: Participation of SO2 in the oxidation of ArSCF3−•.
Scheme 50: Electron transfer cascade involving SO2 and MV.
Scheme 51: Four stages of the SRN1 mechanism for thiol perfluoroalkylation.
Scheme 52: A double role of MV in the catalysis of RFI reactions with aryl thiols.
Scheme 53: Photochemical reaction of pentafluoroiodobenzene with trifluoromethyl disulfide.
Scheme 54: N- Trifluoromethyl-N-nitrosobenzene sulfonamide – a source of CF3• radicals [212,213].
Scheme 55: Radical trifluoromethylation of organic disulfides with ArSO2N=NCF3.
Scheme 56: Barton’s S-perfluoroalkylation reactions [216].
Scheme 57: Decarboxylation of thiohydroxamic esters in the presence of C6F13I.
Scheme 58: Reactions of thioesters of trifluoroacetic and trifluoromethanesulfonic acids in the presence of ar...
Scheme 59: Perfluoroalkylation of polychloropyridine thiols with xenon perfluorocarboxylates or XeF2 [222,223].
Scheme 60: Interaction of Xe(OCORF)2 with nitroaryl disulfide [227].
Scheme 61: Bi(CF3)3/Cu(OCOCH3)2 trifluoromethylation of thiophenolate [230].
Scheme 62: Reaction of fluorinated carbanions with aryl sulfenyl chlorides.
Scheme 63: Reaction of methyl perfluoromethacrylate with PhSCl in the presence of fluoride.
Scheme 64: Reactions of ArSCN with potassium and magnesium perfluorocarbanions [237].
Scheme 65: Reactions of RFI with TDAE and organic disulfides [239,240].
Scheme 66: Decarboxylation of perfluorocarboxylates in the presence of disulfides [245].
Scheme 67: Organization of a stable form of “CF3−” anion in the DMF.
Scheme 68: Silylated amines in the presence of fluoride can deprotonate fluoroform for reaction with disulfide...
Figure 7: Other examples of aminomethanols [264].
Scheme 69: Trifluoromethylation of diphenyl disulfide with PhSO2CF3/t-BuOK.
Scheme 70: Amides of trifluoromethane sulfinic acid are sources of CF3− anion.
Scheme 71: Trifluoromethylation of various thiols using “hyper-valent” iodine (III) reagent [279].
Scheme 72: Trifluoromethylation of p-nitrothiophenolate with diaryl CF3 sulfonium salts [280].
Scheme 73: Trifluoromethyl transfer from dibenzo (CF3)S-, (CF3)Se- and (CF3)Te-phenium salts to thiolates [283].
Scheme 74: Multi-stage paths for synthesis of dibenzo-CF3-thiophenium salts [61].
Can we measure catalyst efficiency in asymmetric chemical reactions? A theoretical approach
- Shaimaa El-Fayyoumy,
- Matthew H. Todd and
- Christopher J. Richards
Beilstein J. Org. Chem. 2009, 5, No. 67, doi:10.3762/bjoc.5.67
- industrial uses perhaps because of issues of safety, but these are difficult to quantify for our purposes. Nevertheless ACE combines the key parameters describing the practical usefulness of a catalyst for a laboratory not involved in bulk manufacture. While it is our aim to define a simple formula allowing
Graphical Abstract
Figure 1: Definition of Asymmetric Catalyst Efficiency (ACE).
